LON:DEST Destiny Pharma (DEST) Share Price, News & Analysis → The Department of Defense Has a New Drone Contractor (From The Tomorrow Investor) (Ad) Free DEST Stock Alerts GBX 18 -0.25 (-1.37%) (As of 05/7/2024 ET) Add Compare Share Share Today's Range 17.62▼ 18.5050-Day Range 16.25▼ 3452-Week Range 13.20▼ 84Volume225,537 shsAverage Volume520,592 shsMarket Capitalization£17.16 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider TradesStock AnalysisAnalyst ForecastsChartCompetitorsHeadlinesInsider Trades Get Destiny Pharma alerts: Email Address Ad AltimetryUrgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.Click here to access… About Destiny Pharma Stock (LON:DEST)Destiny Pharma plc, a biotechnology company, focuses on the discovery, development, and commercialization of novel medicines to prevent serious infections in the United Kingdom. The company is involved in developing NTCD-M3 that is in Phase II clinical trial for the prevention of recurrent Clostridioides diffcile infections; XF-73 Nasal, which is in Phase II clinical trial for the prevention of post-surgical staphylococcal infection; and XF-73 Dermal that is in preclinical stage for the treatment of skin infections of antibiotic resistant bacteria, as well as superficial skin infections of antibiotic resistant bacteria. It also develops SPOR-COV, biotherapeutic product, which is in preclinical stage for the prevention of COVID-19 and other viral respiratory infections; and XF Drugs Research/Biofilms that is in preclinical stage for the treatment of antibiotic resistant biofilm and bacterial aggregate associated infections. In addition, the company is involved in the development of XF drugs for the treatment of respiratory, dermal, oral and ocular infections. Destiny Pharma plc has collaboration agreements with China Medical System Holdings Limited; SporeGen Limited; Sebela Pharmaceuticals; the University of Southampton; Aston University; the University of Sheffield; National Biofilms Innovation Centre; National Institute of Allergy and Infectious Diseases; Cystic Fibrosis Foundation; Cardiff University; and Tianjin Medical University. The company was incorporated in 1996 and is based in Brighton, the United Kingdom.Read More DEST Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart DEST Stock News HeadlinesMay 7, 2024 | msn.comRedfall review: multiplayer sucks the life out of a promising vampire shooterMay 7, 2024 | msn.comCovid Vaccine – Is It India's Voldemort?May 7, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 26, 2024 | msn.com‘Covert City’ Review: The Cold War in MiamiApril 26, 2024 | msn.com‘The Last of Us,’ ‘Bluey,’ ‘Poker Face,’ ‘The Bear’ Among Peabody Award Nominations as More 2024 Contenders Are AnnouncedApril 25, 2024 | lse.co.ukTRADING UPDATES: Norcros sells Johnson Tiles UK; Trifast trading wellApril 25, 2024 | msn.comMARKET REPORT: Meta sheds £130bn value after AI spending fearsApril 8, 2024 | usatoday.comCarol Ann Langford’s Legacy of Servant Leadership Informs Her Mission to Nurture Human InnovationMay 7, 2024 | Altimetry (Ad)Urgent Nvidia WarningCould Steve Job's 'Final Prophecy' Make You Rich? Just before he died, Steve Jobs issued a "Final Prophecy" that's now coming true... and making some people rich. In one recent 90-day stretch, 50 companies related to Jobs' "Final Prophecy" soared by 100% or more. What was Steve Jobs' last big prediction, and how can you get in on it? Professor Joel Litman explains everything... including the surprising group of stocks moving higher, and his No. 1 favorite stock in this space.April 3, 2024 | msn.comMarcelo Weigandt opens up on Messi, Maradona, Inter Miami and why he wears No. 57March 28, 2024 | msn.com'Lefties losing it': Dr Jordan Peterson gives 'masterclass in lefty annihilation'March 20, 2024 | nytimes.comOprah, Ozempic and UsMarch 18, 2024 | bizjournals.comNKU College of Law, UK College of Medicine plan $150M riverfront facility in CovingtonMarch 16, 2024 | msn.comHolding up half the skyMarch 15, 2024 | msn.comIndia Mobilizes Aid Amid Haiti’s Gang Violence: 24-Hour Helpline and Evacuation Plans in MotionMarch 12, 2024 | msn.comRBI goes after ‘peer to peer’ transactions – Cred, NoBroker on radarMarch 11, 2024 | msn.comUR's New Vaccinology Programme Is a Step in the Right DirectionMarch 8, 2024 | abcnews.go.com'I believe in America': Fired-up Biden uses State of the Union to skewer GOP, his 'predecessor'March 8, 2024 | nytimes.comAn Instant Crush Over Mashed PotatoesMarch 6, 2024 | bizjournals.comBayer CEO on how he plans to fix a 'broken' companyFebruary 23, 2024 | dailymail.co.ukITV orders a drama depicting the contaminated blood scandal after Mr Bates Vs The Post Office sparked nationwide uproarFebruary 22, 2024 | morningstar.comDestiny Pharma PLC DESTFebruary 19, 2024 | msn.comHow George Washington can save Israel, and NetanyahuFebruary 18, 2024 | msn.comRFK Jr. has a distinct appeal when it comes to young male votersFebruary 9, 2024 | benzinga.comDestiny Pharma Stock (OTC:DTTYF), Analyst Ratings, Price Targets, PredictionsFebruary 6, 2024 | msn.comHarsh Goenka's vision: India needs to rediscover and recover its old mojoFebruary 4, 2024 | msn.comWant to live forever? The longevity doctor will see you now…See More Headlines Receive DEST Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Destiny Pharma and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings9/17/2020Today5/07/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeLON SectorMedical Industry Biotechnology Sub-IndustryN/A Current SymbolLON:DEST CUSIPN/A CIKN/A Webwww.destinypharma.com Phone+44-1273-704440FaxN/AEmployees24Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)GBX (0.06) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income£-5,660,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-67.29% Return on Assets-44.90% Debt Debt-to-Equity RatioN/A Current Ratio9.89 Quick Ratio11.10 Sales & Book Value Annual Sales£135,028.00 Price / Sales124.80 Cash FlowGBX 6.57 per share Price / Cash Flow2.69 Book ValueGBX 10 per share Price / Book1.77Miscellaneous Outstanding Shares95,310,000Free FloatN/AMarket Cap£16.85 million OptionableNot Optionable Beta0.24 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report Key ExecutivesDr. William Guy Love (Age 62)Founder, Chief Scientific Officer & Director Comp: $265kMr. Shaun Claydon ACA (Age 56)CFO, Company Secretary & Director Comp: $286kDr. Debra Barker M.D. (Age 62)MSc., Interim CMO & Senior Independent Director Comp: $41kMr. Christopher John Tovey BSc (Age 59)CEO & Director Key CompetitorsOncimmuneLON:ONCOptiBiotix HealthLON:OPTIOxford BioDynamicsLON:OBDSareumLON:SARSkinBioTherapeuticsLON:SBTXView All CompetitorsInsidersNick RodgersBought 49,477 shares on 5/25/2023Total: £1.53 M ($31.00/share)View All Insider Transactions DEST Stock Analysis - Frequently Asked Questions How have DEST shares performed in 2024? Destiny Pharma's stock was trading at GBX 70 at the beginning of 2024. Since then, DEST shares have decreased by 74.3% and is now trading at GBX 18. View the best growth stocks for 2024 here. How were Destiny Pharma's earnings last quarter? Destiny Pharma plc (LON:DEST) posted its quarterly earnings data on Thursday, September, 17th. The company reported ($5.50) earnings per share for the quarter. What other stocks do shareholders of Destiny Pharma own? Based on aggregate information from My MarketBeat watchlists, some companies that other Destiny Pharma investors own include Dynavax Technologies (DVAX), AFPO.L (AFPO), Aldeyra Therapeutics (ALDX), Ares Capital (ARCC), BioCryst Pharmaceuticals (BCRX), BioNTech (BNTX), Centamin (CEY), Countryside Partnerships (CSP), Enbridge (ENB) and EQTEC (EQT). How do I buy shares of Destiny Pharma? Shares of DEST stock and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.Compare Top Brokerages Here. This page (LON:DEST) was last updated on 5/7/2024 by MarketBeat.com Staff From Our PartnersThe Department of Defense Has a New Drone ContractorThe Tomorrow InvestorTech GIANT’s Plans to Revolutionize Crypto…Crypto 101 MediaThe A.I. story nobody is telling you (Read ASAP)TradeSmithUrgent Nvidia WarningAltimetryThe asset beating inflation by 4xColonial MetalsThe 2024 Gold Rush: Unleashing Market PotentialPriority GoldHe Is Giving Away BitcoinCrypto Swap ProfitsObama’s Forever Term [exposed]Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Destiny Pharma plc Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
